graph Evidence gap map comparisons
pembrolizumab based treatment
pembrolizumab plus SoC
mBC - TNBC - L1 - all population 7   
Comparator:  vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;